Eunice Wang, MD

Articles

Dr. Wang on the Potential Impact of Menin Inhibitors in AML

June 11th 2021

Eunice Wang, MD, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia.

Dr. Wang on Preliminary Findings From the KOMET-001 Trial in Relapsed/Refractory AML

December 15th 2020

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML

February 20th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia.

Dr. Wang Discusses Treatment Options for FLT3-Mutated AML

February 9th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses treatment options for patients with FLT3-mutated acute myeloid leukemia.

Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML

January 30th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.

Dr. Wang Discusses FLT3 Mutations in AML

June 25th 2017

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia.